TAO TREASURES, LLC — Department of Defense SBIR Phase II: DHA201-003
TAO TREASURES, LLC — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- At $1,649,092, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Topic code DHA201-003 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $1,649,092
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase II
- Topic
- DHA201-003
- Solicitation
- 20.1
- NAICS
- —
- Place of performance
- MD
- Period
- 2023-08-18 → 2024-12-31
Description
Tao Treasures LLC, dba Nanobiofab (NBF), hereafter referred to as Nanobiofab, is developing a revolutionary RAPID-iNose solution to address the urgent need for an intelligent wound dressing system that integrates bacterial infection detection with NPWT. The RAPID-iNose employs low-cost, highly sensitive, accurate, miniaturizable, AI-powered gas sensors for rapid, continuous, and real-time monitoring of volatile organic compounds (VOCs) produced by microorganisms during growth, allowing for species-specific identification. RAPID-iNose's gas-sensor-based diagnostics can significantly decrease microbial identification time from days to hours or even minutes. This technology can also improve accuracy by identifying a broader range of microorganisms than traditional culture-based methods, as VOC production can occur even when standard culture conditions are not met. Furthermore, gas-sensor-based diagnostics enable real-time monitoring of microbial growth in clinical microbiology, leading to more targeted and timely treatment of infections. Key features of RAPID-iNose include: • Early detection within a 24-hour window, enabling prompt intervention and reducing complications in military personnel • A lower limit of detection compared to culture-based approaches, ensuring accurate identification of wound infections • Partial insensitivity to contaminants, making it suitable for field and hospital environments • Cost-effectiveness for widespread distribution among military units • Reduced training time and qualification requirements for laboratory personnel, expediting the implementation of this technology in military healthcare settings